A Phase 1 interventional study of Sulthiame in Epilepsy, sponsored by Centre Hospitalier Universitaire Vaudois. Completed at 1 site in Switzerland. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-18.
Sponsored by Centre Hospitalier Universitaire Vaudois · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Epilepsy with a site in Switzerland — 10 open to participants now, 11 under way, 1 of them phase 3. Epilepsy · Switzerland.
Among the 37 studies in Epilepsy with a site in Switzerland, this one is the 26th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2018, is the only one in phase 1, and was the 18th registered.
1,848 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →10 of the 37 studies in Epilepsy with a site in Switzerland are open now. Recruiting first, the newest first:
University of Zurich · Sites in Switzerland
Ages 18–65 · Healthy volunteers
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Istituto Giannina Gaslini · Sites in Switzerland, United States, Australia and 10 more countries
Pierre Mégevand · Sites in Switzerland
Ages 18+
University of Zurich · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 283 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 138 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 12 · Phase 4 1
First in 2005; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 120 across the 27 interventional studies, 270 across the 10 observational. Of the 25 that completed or were terminated, 11 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 37 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire Vaudois is the lead sponsor of 208 studies on the registry; 48 are open to participants now.
Centre Hospitalier Universitaire Vaudois has 2 studies filed under Epilepsy — fewer than ten, so there is no comparison to draw.
5 of the studies in Epilepsy with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT07881185Istituto Giannina GasliniArtificial Intelligence for Brain MRI Analysis in Epilepsy | 2026-12-31 |
| NCT06138808Duke University5-SENSE Score Validation Study | 2027-01 |
| NCT05335187Pierre MégevandHybrid Micro-macro Electrodes in Patients With Epilepsy | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies in Epilepsy with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This preliminary pilot exploration aims at specifying the pharmacokinetic parameters of sulthiame, formulated as an immediate release tablet, thus helping to design proper clinical trials for the future assessment of new paediatric formulations currently under development. The clinical tolerability to single doses of sulthiame will also be closely monitored to orient future trials.
Sulthiame (or sultiame), marketed in the 60's in Germany, Austria, Switzerland, Israel, Australia and Japan under the brand name Ospolot®, has progressively become the therapeutic first choice in benign focal epilepsies of childhood in these countries.
Its antiepileptic activity is thought to result from the inhibition of various subtypes of carbonic anhydrase (hCA), in particular cytosolic hCA II, thus inducing a degree of intracellular acidification sufficient to stabilize seizure-eliciting neurons. The pharmacokinetic profile of sulthiame was scarcely studied in humans.
Sulthiame is a suitable candidate for paediatric formulation optimization, as the current formulation (coated tablets of 50 or 200 mg) allows neither precise and adapted dosing, nor convenient administration to young children.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of sulthiame (Ospolot® tablets) * Period I: 50 mg * Period II: 100 mg * Period III: 200 mg given 3 weeks apart
Drug: Sulthiame
Single dose (50, 100, 200 mg)
Also known as: Ospolot
Elimination half-life of sultiame after single doses of 50, 100 and 200 mg of sulthiame in 4 healthy volunteers.
Sultiame plasma concentration will be measured at predefined times after dose administration, the results will be plotted graphically and traditional pharmacokinetic calculations (log-linear regression) will be used to derive estimates of this pharmacokinetic parameter. This is a descriptive outcome and no statistical test is applied.
Time frame: 9 weeks
Area Under curve (AUC) of sultiame after single doses of 50, 100 and 200 mg of sulthiame in 4 healthy volunteers.
Sultiame plasma concentration will be measured at predefined times after dose administration, the results will be plotted graphically and traditional pharmacokinetic calculations (numerical integration through trapezoidal rule) will be used to derive estimates of this pharmacokinetic parameter. This is a descriptive outcome and no statistical test is applied.
Time frame: 9 weeks
Systemic drug clearance of sultiame after single doses of 50, 100 and 200 mg of sulthiame in 4 healthy volunteers.
Sultiame concentration will be measured at predefined times after dose administration, the results will be plotted graphically and traditional pharmacokinetic calculations (ratio of administered dose over AUC) will be used to derive estimates of this pharmacokinetic parameter. This is a descriptive outcome and no statistical test is applied.
Time frame: 9 weeks
Distribution volume of sultiame after single doses of 50, 100 and 200 mg of sulthiame in 4 healthy volunteers.
Sultiame plasma concentration will be measured at predefined times after dose administration, the results will be plotted graphically and traditional pharmacokinetic calculations (product of clearance by half-life divided by the logarithm of 2) will be used to derive estimates of this pharmacokinetic parameter. This is a descriptive outcome and no statistical test is applied.
Time frame: 9 weeks
Dose linearity of plasma exposure to sultiame
A linear regression model will be applied to AUC as a function of dose, and the conclusion of dose linearity will be accepted if the model appears statistically non-inferior to an ANOVA model.
Time frame: 9 weeks
Plasma free fraction of sultiame
The ratios of free over total plasma concentrations, and of whole blood over total plasma concentrations will be calculated, and its stability over the range of concentrations will be checked by statistical analysis for trend.
Time frame: 9 weeks
Erythrocyte binding of sultiame
The ratios of free over total plasma concentrations, and of whole blood over total plasma concentrations will be calculated, and its stability over the range of concentrations will be checked by statistical analysis for trend.
Time frame: 9 weeks
Validation of a liquid chromatography-mass spectrometry (LC-MS/MS) assay method for the determination of sultiame in biological fluids
The analytical method used for the study will be assessed for its sensitivity (estimation of detection and quantification limits), precision (estimation of intra-day and inter-day reproducibility) and accuracy (estimation of sultiame recovery using spiked samples). The analytical method will be considered validated if all criteria are within the acceptance range set by FDA/ICH recommendations.
Time frame: 9 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Feb 2018 to primary completion in May 2018, 3 months.
Of 55 phase 1 interventional studies under Epilepsy, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 22. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sulthiame
Centre Hospitalier Universitaire Vaudois →